Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Brain Neoplasms 2Meningeal Carcinomatosis 1Glioblastoma 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × XL647 × Clear all
NCT00364780 2022-05-13

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Kadmon Corporation, LLC

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00522145 2022-05-13

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Kadmon Corporation, LLC

Phase 2 Completed
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡